Study on Serum Zinc and Selenium Levels in Epileptic Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Farahani Heidar, Arak University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01764516
First received: January 5, 2013
Last updated: NA
Last verified: January 2013
History: No changes posted
  Purpose

This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.


Condition
Generalized Epileptic

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Week
Official Title: Arak University of Medical Sciences , Ministry of Health and Education,I.R.Iran

Resource links provided by NLM:


Further study details as provided by Arak University of Medical Sciences:

Primary Outcome Measures:
  • Study on Serum Zinc and Selenium Levels in Epileptic Patients [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
    decrement in serum zinc and selenium level


Secondary Outcome Measures:
  • Comparison between the selenium levels by gender in two groups [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Serum were analysis for zinc and selenium


Enrollment: 40
Study Start Date: November 2011
Study Completion Date: May 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Zinc level (micro gram per deciliter)
In all cases
Selenium level (micro gram per deciliter)
In all cases
Zinc level in male (micro gram per deciliter)
Selenium level in male (micro gram per deciliter)
Zinc level in Female (micro gram per decilitre)
Selenium level in Female (micro gram per decilitre)

Detailed Description:

Forty patients aged 18 to 50 years visiting Vali-Asr hospital in Arak, I.R. Iran, who were diagnosed with generalized form of epilepsy by a neurologist for the first time were recruited as cases. The control group (n=40) was selected from healthy individuals, in whom no disease was diagnosed until this study, and were matched to the case group by age, sex, and economical status.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

all generalized and single epileptic patiants which were identify for fist time

Criteria

Inclusion Criteria:

New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications,

Exclusion Criteria:

presence of above criteria as well as, generalized and single epileptic cases under treatment

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01764516

Locations
Iran, Islamic Republic of
Vali-Asr Hospital
Arak, Central province, Iran, Islamic Republic of
Sponsors and Collaborators
Arak University of Medical Sciences
Investigators
Principal Investigator: Heidar N Farahani, PhD Department of Biochemistry,Arak medical sciences university
  More Information

No publications provided

Responsible Party: Dr. Farahani Heidar, faculity of medicine, department of biochemistry, Arak University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01764516     History of Changes
Other Study ID Numbers: f110@1958, f110@19588, f110@19588, f110@19588
Study First Received: January 5, 2013
Last Updated: January 5, 2013
Health Authority: Iran: Ethics Committee
Iran: Ministry of Health

Keywords provided by Arak University of Medical Sciences:
zinc
selenium
serum
epilepsy
antioxidants

Additional relevant MeSH terms:
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Selenium
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on April 16, 2014